Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis: Insights by Disease-Modifying Therapy

Abstract

Background

Sodium glucose co-transporter 2 inhibitors (SGLT2i) improve outcomes in heart failure (HF), but evidence in transthyretin cardiac amyloidosis (ATTR-CM)—particularly in patients not receiving disease-modifying therapy (DMT)—remains limited.

Objectives

This study aimed to evaluate the efficacy and safety of SGLT2i in ATTR-CM, stratified by DMT.